| Literature DB >> 30815844 |
Pablo Villoslada1, Gemma Vila2, Valeria Colafrancesco2, Beatriz Moreno2, Begoña Fernandez-Diez2, Raquel Vazquez2, Inna Pertsovskaya2, Irati Zubizarreta2, Irene Pulido-Valdeolivas2, Joaquin Messeguer3, Gloria Vendrell-Navarro3, Jose Maria Frade4, Noelia López-Sánchez4, Meritxell Teixido5, Ernest Giralt5, Mar Masso6, Jason C Dugas7, Dmitri Leonoudakis7, Karen D Lariosa-Willingham7, Lawrence Steinman8, Angel Messeguer3.
Abstract
The development of neuroprotective therapies is a sought-after goal. By screening combinatorial chemical libraries using in vitro assays, we identified the small molecule BN201 that promotes the survival of cultured neural cells when subjected to oxidative stress or when deprived of trophic factors. Moreover, BN201 promotes neuronal differentiation, the differentiation of precursor cells to mature oligodendrocytes in vitro, and the myelination of new axons. BN201 modulates several kinases participating in the insulin growth factor 1 pathway including serum-glucocorticoid kinase and midkine, inducing the phosphorylation of NDRG1 and the translocation of the transcription factor Foxo3 to the cytoplasm. In vivo, BN201 prevents axonal and neuronal loss, and it promotes remyelination in models of multiple sclerosis, chemically induced demyelination, and glaucoma. In summary, we provide a new promising strategy to promote neuroaxonal survival and remyelination, potentially preventing disability in brain diseases.Entities:
Keywords: Neuroprotection; glaucoma; multiple sclerosis; neurodegenerative diseases; neuroinflammation
Mesh:
Substances:
Year: 2019 PMID: 30815844 PMCID: PMC6694325 DOI: 10.1007/s13311-019-00717-4
Source DB: PubMed Journal: Neurotherapeutics ISSN: 1878-7479 Impact factor: 7.620